Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3749)	5/11/2001 10:07:11 AM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

Peter, Is it not also encouraging for the Genome companies and the treatments that will result from their research? Isn't that the ultimate in designer drugs? Hopefully the expedited FDA process will become the norm rather than their recent treatment of QLTI. (i.e. - We know you've got 3 years of excellent clinical results, but do another trial anyway!!!) Ian. It's the first "cure" or perhaps "semi-cure" for a cancer that doesn't involve nasty chemo or radiation. Further, it was very much a "designer drug" based on an understanding of the disease at a molecular level, rather than something that popped out in a random screening.